BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 23988576)

  • 21. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study.
    Birnbaum DJ; Turrini O; Vigano L; Russolillo N; Autret A; Moutardier V; Capussotti L; Le Treut YP; Delpero JR; Hardwigsen J
    Ann Surg Oncol; 2015 Mar; 22(3):1000-7. PubMed ID: 25190116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors.
    Dhall D; Mertens R; Bresee C; Parakh R; Wang HL; Li M; Dhall G; Colquhoun SD; Ines D; Chung F; Yu R; Nissen NN; Wolin E
    Hum Pathol; 2012 Apr; 43(4):489-95. PubMed ID: 21937080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival and prognostic factors in well-differentiated pancreatic neuroendocrine tumors.
    Boyar Cetinkaya R; Vatn M; Aabakken L; Bergestuen DS; Thiis-Evensen E
    Scand J Gastroenterol; 2014 Jun; 49(6):734-41. PubMed ID: 24679166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Geminin expression in pancreatic neuroendocrine tumors: possible new marker of malignancy.
    Aizawa M; Kojima M; Gotohda N; Fujii S; Katoh Y; Kinoshita T; Takahashi S; Konishi M; Kinoshita T; Ochiai A
    Pancreas; 2012 May; 41(4):512-7. PubMed ID: 22504377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study.
    Rindi G; Falconi M; Klersy C; Albarello L; Boninsegna L; Buchler MW; Capella C; Caplin M; Couvelard A; Doglioni C; Delle Fave G; Fischer L; Fusai G; de Herder WW; Jann H; Komminoth P; de Krijger RR; La Rosa S; Luong TV; Pape U; Perren A; Ruszniewski P; Scarpa A; Schmitt A; Solcia E; Wiedenmann B
    J Natl Cancer Inst; 2012 May; 104(10):764-77. PubMed ID: 22525418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinicopathological features of pancreatic neuroendocrine neoplasms: a retrospective analysis of 64 cases].
    Yao W; Wang W; Li G
    Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):287-93. PubMed ID: 24989916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
    Lam JS; Shvarts O; Said JW; Pantuck AJ; Seligson DB; Aldridge ME; Bui MH; Liu X; Horvath S; Figlin RA; Belldegrun AS
    Cancer; 2005 Jun; 103(12):2517-25. PubMed ID: 15880379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of 100 consecutive cases of resectable pancreatic neuroendocrine neoplasms: clinicopathological characteristics and long-term outcomes.
    Cheng Y; Zhan H; Wang L; Xu J; Zhang G; Zhang Z; Hu S
    Front Med; 2016 Dec; 10(4):444-450. PubMed ID: 27757796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications.
    Strosberg JR; Cheema A; Weber JM; Ghayouri M; Han G; Hodul PJ; Kvols LK
    Ann Surg; 2012 Aug; 256(2):321-5. PubMed ID: 22415420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small intestinal neuroendocrine tumors: prognostic factors and survival.
    Bergestuen DS; Aabakken L; Holm K; Vatn M; Thiis-Evensen E
    Scand J Gastroenterol; 2009; 44(9):1084-91. PubMed ID: 19572232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease.
    Lopez-Aguiar AG; Ethun CG; Postlewait LM; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Sarmiento JM; Kooby DA; Staley CA; Maithel SK; Cardona K
    Ann Surg Oncol; 2018 Jan; 25(1):290-298. PubMed ID: 29079920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories.
    Milione M; Maisonneuve P; Spada F; Pellegrinelli A; Spaggiari P; Albarello L; Pisa E; Barberis M; Vanoli A; Buzzoni R; Pusceddu S; Concas L; Sessa F; Solcia E; Capella C; Fazio N; La Rosa S
    Neuroendocrinology; 2017; 104(1):85-93. PubMed ID: 26943788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the World Health Organization 2010 grading system in surgical outcome and prognosis of pancreatic neuroendocrine tumors.
    Yang M; Tian BL; Zhang Y; Su AP; Yue PJ; Xu S; Wang L
    Pancreas; 2014 Oct; 43(7):1003-8. PubMed ID: 24945681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm.
    Mirkin KA; Hollenbeak CS; Wong J
    J Surg Res; 2017 May; 211():206-214. PubMed ID: 28501118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reassessment of the current American Joint Committee on Cancer staging system for pancreatic neuroendocrine tumors.
    Qadan M; Ma Y; Visser BC; Kunz PL; Fisher GA; Norton JA; Poultsides GA
    J Am Coll Surg; 2014 Feb; 218(2):188-95. PubMed ID: 24321190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations.
    Russolillo N; Vigano' L; Razzore P; Langella S; Motta M; Bertuzzo F; Papotti M; Ferrero A
    Eur J Surg Oncol; 2015 Jun; 41(6):751-7. PubMed ID: 25887286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ki-67 and presence of liver metastases identify different progression-risk classes in pancreatic neuroendocrine neoplasms (pNEN) undergoing resection.
    Milione M; Maisonneuve P; Pellegrinelli A; Spaggiari P; Centonze G; Coppa J; Delconte G; Droz Dit Busset M; Lanhazo O; Pruneri G; Mazzaferro V
    Eur J Surg Oncol; 2019 May; 45(5):755-760. PubMed ID: 30366875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors.
    Crippa S; Partelli S; Zamboni G; Scarpa A; Tamburrino D; Bassi C; Pederzoli P; Falconi M
    Surgery; 2014 Jan; 155(1):145-53. PubMed ID: 24646958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.